Keiichi Ishihara

Publication Activity (10 Years)

Years Active: 2015-2023
Publications (10 Years): 7

Top Topics

Neural Stem Cells

Subarachnoid Hemorrhage

Top Venues

Life (Basel, Switzerland)

The Journal of pharmacology and experimental therapeutics

Brain pathology (Zurich, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Keiichi Ishihara, Kazuyuki Takata, Ken-Ichi Mizutani
Involvement of an Aberrant Vascular System in Neurodevelopmental, Neuropsychiatric, and Neuro-Degenerative Diseases. Life (Basel, Switzerland) 13 (1) (2023)
Keiichi Ishihara, Kazuyuki Takata, Ken-Ichi Mizutani
Involvement of an Aberrant Vascular System in Neurodevelopmental, Neuropsychiatric, and Neuro-Degenerative Diseases. Life (Basel, Switzerland) 13 (1) (2023)
Keiichi Ishihara, Kazuyuki Takata, Ken-Ichi Mizutani
Involvement of an Aberrant Vascular System in Neurodevelopmental, Neuropsychiatric, and Neuro-Degenerative Diseases. Life (Basel, Switzerland) 13 (1) (2023)
Keiichi Ishihara, Kazuyuki Takata, Ken-Ichi Mizutani
Involvement of an Aberrant Vascular System in Neurodevelopmental, Neuropsychiatric, and Neuro-Degenerative Diseases. Life (Basel, Switzerland) 13 (1) (2023)
Keiichi Ishihara
Genes Associated with Disturbed Cerebral Neurogenesis in the Embryonic Brain of Mouse Models of Down Syndrome. Genes 12 (10) (2021)
Keiichi Ishihara, Ryohei Shimizu, Kazuyuki Takata, Eri Kawashita, Kenji Amano, Atsushi Shimohata, Donovan Low, Takeshi Nabe, Haruhiko Sago, Warren S Alexander, Florent Ginhoux, Kazuhiro Yamakawa, Satoshi Akiba
Perturbation of the immune cells and prenatal neurogenesis by the triplication of the Erg gene in mouse models of Down syndrome. Brain pathology (Zurich, Switzerland) 30 (1) (2019)
Shiho Kanai, Keiichi Ishihara, Eri Kawashita, Toshiyuki Tomoo, Kazuhiro Nagahira, Yasuhiro Hayashi, Satoshi Akiba
ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease. The Journal of pharmacology and experimental therapeutics 356 (3) (2015)